Select your country or region to view content specific to your country.
Seegene to supply diagnostic reagents to public hospitals in Tuscany for five yearsBidding scale increased by six-fold with non-COVID products accounting for 43% due to the clinical utility of molecular diagnosticsPositive impact on bidding in other regions and continuous growth of non-COVID products are expected Seoul (November 18, 2022) Seegene Inc. (096530), South Korea’s leading molecular diagnostics company, has won a €45 million (about KRW 62.7 billion) tender to supply diagnostic reagents with the regional government of Tuscany, Italy.The company announced that its local subsidiary in Italy, Arrow Diagnostics S.r.l., was selected as a supplier in the bid for diagnostic reagents conducted every five years by the Tuscan government. The supply scale, which was 10 billion KRW in 2016, has also increased significantly by more than six-fold. This increase is due to the clinical utility of molecular diagnostics, which has been recognized in medical facilities, such as hospitals, during the pandemic. With the contract, Seegene will not only supply COVID-19 test kits but also supply diagnostic reagents for the detection of human papillomavirus infections, sexually transmitted infections, antibiotic resistance determinants, and mycobacterium tuberculosis to 13 public hospitals in Tuscany from January 2023. According to the supply agreement in the contract, COVID-19 test and non-COVID products account for 57% and 43%, respectively. Seegene explained that its successes in bidding for the contract are attributed to Seegene’s multiplex PCR technology and the application of the diagnostic reagent to its automated PCR system. Also, it is believed that the company has contributed to Italy’s overcoming of the pandemic by supplying COVID-19 tests for 7.15 million people to the COVID-19 Emergency Response Committee under the Italian Ministry of Defense in April 2021. “I hope that the signing of this contract will have a positive impact on our chances of winning tenders in other regions in the future and serve as a driver for the continued sales growth of our non-COVID products” said Maccheroni Franco, CEO of Arrow Diagnostics S.r.l.
Nov 18, 2022View Detail >
Company has taken part in the Annual Scientific Meeting & Clinical Lab Expo since 2007This year’s event showcased its In-life PCR campaign and STARlet-AIOSSeegene also displayed Novaplex™ assays, including a test for detecting the monkeypox virus Seoul (July 28, 2022) Seegene Inc. (096530), South Korea’s leading molecular diagnostics company, took part in the 2022 American Association of Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo in Chicago between July 26-28. Seegene showcased its ‘In-life PCR’ campaign and its automated PCR Solution ‘STARlet-AIOS,’ as well as a suite of Novaplex™ assays, including a test for detecting the monkeypox virus.The AACC meeting, now in its 74th year, is the world’s largest gathering for the clinical laboratory and diagnostics industry. More than 200 global companies, participated in this year’s event. Seegene has taken part since 2007. In-life PCR: Keeping communities safe through regular testingSeegene’s In-life PCR campaign is a global initiative that emphasizes regular testing of COVID-19, influenza, and cold viruses to identify infected individuals with mild or no symptoms. This, in turn, may help curb widespread transmissions within communities. The campaign will target venues that require face-to-face interactions, such as schools, workplaces, and nursing homes. Seegene will use the Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay, which can simultaneously detect COVID-19, flu A and B, and respiratory syncytial virus (RSV), and will provide the necessary PCR instruments.At the AACC meeting, Seegene shared the campaign’s mission with participants and potential partners. The company recently partnered with a test center in Vietnam to launch the campaign and is working to expand the initiative to other regions, including Europe and the Middle East. Enabling PCR testing at small clinics with fully automated STARlet-AIOSSeegene’s STARlet-AIOS (All-in-One System) will provide “hands-free” PCR workflows, from nucleic acid extraction to result analysis. It is a fully automated (sample in – result out) system that can be operated by those with minimal PCR experience. STARlet-AIOS is compatible with a wide range of Seegene’s syndromic assays that can simultaneously test for multiple targets with just a single tube. The company has obtained EU-approval for over 30 tests that can detect COVID-19 and other respiratory illnesses, human papillomavirus (HPV), other sexually transmitted infections (STIs), gastrointestinal infections (GIs), and drug resistance (DR).STARlet-AIOS, which has a smaller footprint compared to other solutions in the market, is composed of independent and detachable PCR component instruments. Test centers can purchase the full set or modify their systems by adding detachable modules. The latter can be an eco-friendly option as it doesn’t require additional resources or manufacturing.The modular nature of the system also makes maintenance convenient, while authorization procedures are easier as it combines pre-approved instruments. It is the world’s first “assembled” solution that enables automated syndromic testing.These features will allow small hospitals, local clinics, and public health centers to integrate STARlet-AIOS into their workflows. The STARlet-AIOS is expected to play a pivotal role in the expansion of Seegene’s In-life PCR campaign. Also, at the 2022 AACC, Seegene displayed its Research Use Only (RUO) product line, Novaplex™, for the U.S. market. This portfolio includes a dedicated test for detecting the monkeypox virus. Seegene recently strengthened its U.S. leadership team as part of efforts to extend its global success to the U.S. market.
Jul 29, 2022View Detail >
Seoul (June 29, 2022) Seegene Inc. (KQ096530), South Korea’s leading molecular diagnostics (MDx) company, has obtained EU approval for its Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay that is compatible with the company’s fully automated ‘AIOS’ (All-in-One System). This is expected to help small hospitals, local clinics, and public health centers effectively identify COVID-19, influenza A and B and respiratory syncytial virus (RSV). Syndromic assay for four respiratory virusesThe Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay can detect six targets associated with the four respiratory viruses. The targets include three distinct COVID-19 genes (S, RdRp, N) to reliably identify positive cases even as new variants emerge. The test also includes two internal controls for proper sampling and testing validation. The product can deliver results within two hours when extraction-free, making it both time and cost-efficient. ‘AIOS,’ first fully automated high throughput MDx system for syndromic testingAIOS, which will be released in July, supports “hands-free” PCR workflows – from nucleic acid extraction to PCR setup, gene amplification and results analysis. As AIOS is a fully automated (sample in – result out) system, it can be operated by those without PCR experience. AIOS is also compact in size and has over 30 compatible assays for syndromic testing to boost efficiency and utility, in contrast to conventional automated PCR solutions in the market that are bigger and have fewer applicable assays that detect only one to three specific targets. AIOS is the world’s first fully automated and “assembled” solution that composes independent and detachable instruments required for PCR, unlike other solutions that operate as a single unit. This makes AIOS convenient to use and maintain, while authorization procedures will be easier as existing instruments and assays can be applied. Such features are expected to allow small hospitals, local clinics, and public health centers to integrate AIOS into their workflows for PCR tests, which had been limited before due to lack of instruments or specialists to operate PCR solutions. Safe return to normalcy with Seegene’s ‘In-life PCR’Healthcare specialists have warned of a resurgence of COVID-19 as early as summer – alongside an increase in flu and cold cases – as immunity from COVID-19 vaccines wane and virus-prevention measures are eased. In response to these concerns, Seegene recently launched the ‘In-life PCR’ initiative to embed PCR tests into our routine by increasing affordability and accessibility. It is aimed at detecting viruses especially among asymptomatic people to help end the COVID-19 outbreak as well as curb widespread transmission to prevent new pandemics. Using the Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay and AIOS, Seegene hopes to establish the foundation for routine testing. *Syndromic testing refers to the process of simultaneously targeting multiple pathogens that have similar symptoms using a single test.
Jun 29, 2022View Detail >
Assay targets monkeypox virus and can deliver results in 90 minutesCompany swiftly rolls out product using its automated assay development system“Seegene will strive to make accurate tests for emerging viruses to help prevent future pandemics” Seoul (June 28, 2022) Seegene Inc. (KQ965390), South Korea’s leading molecular diagnostics (MDx) company has developed a PCR test to detect the monkeypox virus. The Novaplex™ MPXV Assay, which specifically targets the monkeypox virus, was swiftly developed using the company’s AI-based automated test development system, known as SGDDS (Seegene Digitalized Development System), and technologies refined over 20 years of MDx expertise. The World Health Organization says the monkeypox virus is an “evolving health threat that requires collective attention and coordinated action,” calling on member states to step up surveillance, contact tracing and testing. The monkeypox virus has been detected in over 50 nations, with South Korea confirming its first case last week. The strain currently circulating in the Northern Hemisphere has an estimated fatality rate of between 3-6 percent and is considered especially dangerous for children and those with weak immune systems. As with many infectious diseases, accurate diagnosis is crucial as treatments are more effective in the early stages of infection. This makes timely PCR testing vital, especially for individuals with a suspected case, as the incubation period for the monkeypox infection ranges between five to 21 days. The Novaplex™ MPXV Assay can identify positive cases of the monkeypox virus in 90 minutes. The company swiftly developed the product to help curb the worldwide spread. Seegene plans to provide the assays to countries that have detected the virus. “The monkeypox virus outbreak shows that endemic viruses can rapidly spread to the rest of the world and it’s a warning that new pandemics can emerge and threaten our lives at any time,” said Dr. Jong- Yoon Chun, CEO of Seegene. “We will continue our efforts to develop products that can accurately diagnose any virus to help prevent new infectious diseases from taking hold and becoming a pandemic.”
Jun 28, 2022View Detail >
Includes asymptomatic testing at community-based facilities to prevent widespread transmissions Regular testing for COVID-19, flu, RSV crucial for staying safe as anti-virus restrictions are eased PCR tests will be priced affordably, made possible through Seegene’s 20 years of expertise “Full support for countries that join Seegene’s campaign to ensure safe return to normalcy” Seegene Inc. (KQ096530), South Korea’s leading molecular diagnostics company, today unveiled a global initiative for preemptive and routine PCR testing to help individuals stay safe and healthy while living in the COVID-19 era. Dr. Jong-Yoon Chun, CEO of Seegene, says the initiative is designed to help people safely return to normalcy and contribute to global efforts to terminate COVID-19 and prevent future outbreaks. There have been reports of an uptick in influenza and everyday colds which had been absent during the two-year pandemic, as countries worldwide ease social distancing restrictions and lift mask mandates. Experts have also warned that potentially dangerous mutations could go unnoticed due to scaled down PCR testing with governments no longer providing them for free. Individuals are now required to monitor their health at their own expense to stay safe. Seegene’s initiative dubbed 'In-life PCR,' entails 1) asymptomatic testing for early virus detection 2) syndromic respiratory testing as anti-virus restrictions are eased and 3) boosting PCR test accessibility through affordable pricing. ㆍPreemptive asymptomatic testing. PCR tests can identify infected people with mild or even no symptoms. A study by the U.S. CDC found that asymptomatic or presymptomatic individuals are responsible for around 60% of all COVID-19 transmission. Regular asymptomatic testing, even without doctor’s prescription, is expected to help curb widespread infections at community facilities, such as schools, churches, or nursing homes and ensure safe return to normal life. ㆍSyndromic respiratory testing. Syndromic testing is crucial for determining which virus is responsible for a person’s symptoms and what treatment makes sense. Seegene will provide Allplex™ SARS-CoV-2 FluA/FluB/RSV Assay, which can simultaneously detect SARS-CoV-2 (via the N, RdRP and S gene), influenza A and B, and RSV (A/B). The WHO recommends the screening of at least two target genes for SARS-CoV-2. Seegene’s assay identifies three to maintain detection accuracy if new COVID-19 variants emerge. The six-target assay also includes two internal controls for added accuracy. ㆍIncreased PCR test accessibility and affordability. PCR testing has generally been acknowledged as very expensive. Seegene will work with hospitals and labs so that a test can cost around US$12 to boost accessibility and encourage routine testing. High multiplex technologies that build upon the company’s 20+ years of expertise in molecular diagnostics have enabled Seegene to lower the barrier to access. “The ‘$12 PCR testing’ campaign is expected to help Seegene deliver its commitment to making molecular diagnostics accessible to anyone,” said Dr. Chun. “I’m certain that routine PCR testing will be the best solution to help end the COVID-19 pandemic. Seegene will provide full support for cities or countries that join hands with us to better track and curb the outbreak.”
May 25, 2022View Detail >
Nov 15, 2021View Detail >
Jul 09, 2021View Detail >